<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46986">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951027</url>
  </required_header>
  <id_info>
    <org_study_id>GX-G3_HV_1</org_study_id>
    <nct_id>NCT01951027</nct_id>
  </id_info>
  <brief_title>Phase I Study GX-G3 in Healthy Subjects</brief_title>
  <acronym>GX-G3</acronym>
  <official_title>A Dose-block Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Safety, Tolerability, and PK/PD of GX-G3 After Single SC Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      pharmacokinetics/pharmacodynamics of GX-G3 after single subcutaneous administration in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MTD will be determined by DLT occurrence and frequency, and severity and charactoristic of
      adverse event, vital sign, physical examination, ECG, Laboratory test, chest-X-ray will be
      examined for safety evaluation.

      The second purpose is to evaluate pharmacokinetics and pharmacodynamics, and immunogenecity
      will be evaluated to investigate antibody production.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>DLT incidence and frequency after GX-G3 single S.C. injection</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>[DLT criteria: CTCAE V4.03]
Hematologic type: grade 3 Hematologic N.O.S, grade 3 or 4 Leukocytosis
Non-Hematologic: grade 3 N.O.S
N.O.S: not otherwise specified
Leukocytosis: continued more than 5 days, grade 3(&gt;100,000 cells/mm3), or grade 4(clinical manifestations of leucostasis; urgent intervention indicated)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events incidence and frequency at each dose group after GX-G3 single injection</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters after GX-G3 single injection</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC/D, Cmax/D, AUC, AUClast, Cmax, tmax, half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics parameters after GX-G3 single injection</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Emax, Emax, Tmax and AUEClast of absolute neutrophil count(ANC), WBC count and CD34+ cell count</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-G3 12.5 μg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-G3 25 μg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-G3 50 μg/kg or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-G3 100 μg/kg or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-G3 12.5 μg/kg or Placebo</intervention_name>
    <description>Single SC injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>GX-G3(G-CSF-hyFc)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-G3 25 μg/kg or Placebo</intervention_name>
    <description>Single SC injection</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>GX-G3(G-CSF-hyFc)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-G3 50 μg/kg or Placebo</intervention_name>
    <description>Single SC injection</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>GX-G3(G-CSF-hyFc)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-G3 100 μg/kg or Placebo</intervention_name>
    <description>Single SC injection</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>GX-G3(G-CSF-hyFc)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects may be entered in the study only if they meet all of the following criteria:

          1. Are capable of understanding and complying with the requirements of the study and
             have voluntarily signed the informed consent form (ICF);

          2. Healthy male volunteers aged 20-45 years;

          3. Have a body weight of 60-90 kg (inclusive), have a body mass index (BMI) equal to or
             greater than 19 and less than 27 kg/m2;

          4. Are eligible for the study based on screening data (Subjects may participate if
             Investigator considered eligible after looking at other screening data);

        Exclusion Criteria:

        Subjects presenting with any of the following will not be entered in to the study:

          1. Have a history of or current evidence of disease;

          2. Have percent of white blood cell (WBC) or neutrophil &gt; UNL;

          3. Have count of platelet &lt; 100,000/mm3;

          4. Have the longest length of spleen &gt; 16 cm measured by abdomen ultrasonography ;

          5. Have MSSBP ≥ 140 mmHg or ≤ 90 mmHg and/or MSDBP ≥ 95 mmHg or ≤ 50 mmHg; (BP must be
             measured after resting for at least 3 minutes)

          6. Have clinically significant arrhythmia by EKG/ECG;

          7. Are positive for HBV, HCV, HIV;

          8. Have a history of allergy/hypersensitivity or ongoing allergy/hypersensitivity to any
             drug, as judged by the investigator;

          9. Have had any blood donation/ blood loss greater than 400 ml within 8 weeks prior to
             dosing;

         10. Have participated in another clinical trial with investigational drugs within 8 weeks
             of screening period;

         11. Any other conditions that are considered inappropriate or unsafe for subjects by the
             Investigator;

         12. Are considered ineligible by the investigator due to physical findings or laboratory
             values at the screening assessments;

         13. Have a history of G-CSF treatment;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-In Yang, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Genexine, Inc, Clinical development Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae Woo Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUNGNAM NATIONAL UNIVERSITY HOSPITAL Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Jung-gu</city>
        <state>Daejeon</state>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JeaWoo Kim, M.D.</last_name>
      <phone>82-42-280-8618</phone>
      <email>zeusy@cnuh.co.kr</email>
    </contact>
    <investigator>
      <last_name>JeaWoo Kim, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jang Hee Hong, M.D., Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 23, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>DLT</keyword>
  <keyword>Immunogenecity</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
